This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Clovis Oncology (CLVS) Stock Skyrocketed Today
by Ryan McQueeney
Shares of Clovis Oncology (CLVS) opened more than 40% higher on Monday morning after the company announced positive results in a late-stage trial involving its Rubraca therapy--an outcome that could help widen the use of the drug and give Clovis a competitive edge.
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year
by Zacks Equity Research
Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.
Surging Earnings Estimates Signal Good News for Clovis Oncology, Inc. (CLVS)
by Zacks Equity Research
Surging Earnings Estimates and a favorable Zacks rank Signal Good News for Clovis Oncology, Inc. (CLVS)
Implied Volatility Surging for Clovis (CLVS) Stock Options
by Zacks Equity Research
Clovis (CLVS) needs Investors to pay close attention to the stock based on moves in the options market lately.
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain
by Zacks Equity Research
On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).
Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share.
AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
by Zacks Equity Research
AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation
Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula
by Zacks Equity Research
TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.
Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.
Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) saw its shares rise above 5% in the last trading session.
What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
by Zacks Equity Research
In December, Clovis received the FDA nod for its first product, Rubraca, which sent its shares soaring.
by Zacks Equity Research
Clovis Declares Pricing of Upsized Offering of Common Stock
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) announced the pricing of its underwritten public offering of common stock worth $5 million.
Clovis Scales 52-Week High on Early FDA Nod for Rubraca
by Zacks Equity Research
Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.
Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars
by Ryan McQueeney
While there was some afternoon volatility in international markets due to a pair of tragedies in Turkey and Germany, the U.S. indexes were all green on Monday.
Here's Why Clovis Oncology (CLVS) Stock Is Soaring Today
by Ryan McQueeney
Shares of Clovis Oncology (CLVS) soared over 15% in morning trading Monday after the pharmaceutical company received approval for its new PARP inhibitor, "Rubraca," which treats advanced ovarian cancer in women.
GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.